OSE Immunotherapeutics SA (OSE) on Friday reported positive topline results from the Phase 2 TEDOVA trial evaluating Tedopi with or without Keytruda as a maintenance treatment in patients with platinum-sensitive recurrent ovarian cancer.
The trial enrolled patients whose disease had progressed after, or who were ineligible for, PARP inhibitors and bevacizumab. Patients were randomized to receive best supportive care, Tedopi alone, or Tedopi combined with Keytruda following platinum-based therapy.
The study met its primary endpoint, showing a statistically significant improvement in progression-free survival for the Tedopi and Keytruda combination versus best supportive care, with median progression-free survival of 4.1 months compared with 2.8 months.
Compared with Tedopi alone, the addition of Keytruda reduced the risk of disease progression or death by 28%, although the combination was associated with a higher incidence of adverse events, including immune-related events.
The company said the results will be presented at the ASCO Annual Meeting in Chicago on May 30, 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.